Incyte
Incyte Corporation, a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative cancer therapies since its founding in 1991. With a strong focus on oncology, Incyte develops and commercialises novel treatments that address unmet medical needs, particularly in the fields of haematology and solid tumours. The company is renowned for its flagship product, Jakafi (ruxolitinib), which was the first FDA-approved JAK1/JAK2 inhibitor, offering unique therapeutic options for patients with myelofibrosis and polycythaemia vera. Incyte's commitment to research and development has positioned it as a key player in the biopharmaceutical industry, with a robust pipeline of investigational therapies aimed at improving patient outcomes. With a global presence, Incyte continues to make significant strides in advancing cancer care and enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Incyte's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Incyte's score of 35 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Incyte's reported carbon emissions
Incyte Corporation, headquartered in the US, reported a total of approximately 10,216,000 kg CO2e in market-based Scope 1 and 2 emissions for the year 2023. This figure includes about 9,351,000 kg CO2e from Scope 1 emissions and approximately 865,000 kg CO2e from Scope 2 emissions. Additionally, Scope 3 emissions were reported at approximately 4,549,000 kg CO2e from business travel, 360,000 kg CO2e from waste generated in operations, and about 3,830,000 kg CO2e from fuel and energy-related activities. Incyte's emissions data shows a commitment to transparency, with disclosures across all three scopes (1, 2, and 3) for the years 2021 to 2023. However, there are currently no specific reduction targets or initiatives outlined in their reports, indicating a potential area for future development in their climate strategy. The company has demonstrated a consistent emissions intensity, with metrics such as approximately 2.8 kg CO2e per $1 million in revenue and 4.0 kg CO2e per employee for the year 2023. This data reflects Incyte's ongoing efforts to monitor and manage its carbon footprint, although further commitments to reduction targets would enhance its climate action profile. Overall, while Incyte has made strides in emissions reporting, the absence of defined reduction targets suggests an opportunity for the company to strengthen its climate commitments moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 4,775,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 7,451,000 | 0,000,000 | 000,000 | 0,000,000 | 000,000 |
| Scope 3 | 7,165,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Incyte is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
